Advertisement
UK markets open in 1 hour 19 minutes
  • NIKKEI 225

    38,034.11
    +405.63 (+1.08%)
     
  • HANG SENG

    17,695.97
    +411.43 (+2.38%)
     
  • CRUDE OIL

    84.05
    +0.48 (+0.57%)
     
  • GOLD FUTURES

    2,348.20
    +5.70 (+0.24%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,430.93
    +75.87 (+0.15%)
     
  • CMC Crypto 200

    1,387.47
    +4.90 (+0.35%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Coloplast A/S - Transactions in connection with share buy-back programme, week 33 (programme completed)

As mentioned in Announcement no. 02/2021 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The share buyback programme was carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

The following transactions have been executed during the period 16 – 20 August 2021:

Date

Number of shares

Average purchase price, DKK

Transaction value, DKK

16 August 2021

3,000

1,135.37

3,406,110

17 August 2021

5,000

1,140.37

5,701,850

18 August 2021

20,000

1,106.62

22,132,400

19 August 2021

3,400

1,115.92

3,794,128

20 August 2021

4,100

1,116.71

4,578,511

Accumulated until now under the programme

498,487

1,003.02

499,991,460

Henceforth, Coloplast owns 3,279,677 treasury B shares of DKK 1 equal to 1.52% of the company’s total share capital.

ADVERTISEMENT

An overview showing the transaction data for the period 16 – 20 August 2021 is enclosed.

Coloplast's share buyback programme, initiated on 22 February 2021, and as described in Announcement no. 02/2021, is hereby completed.

Kind regards,
Investor Relations
Coloplast A/S
Tel. +45 4911 1800

For further information, please contact

Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111

Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 /+45 4911 3376
Email: dkebj@coloplast.com

Aleksandra Dimovska
Sr. Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com

Press and the media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com

Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917

Website
www.coloplast.com


This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-08.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments